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Abstract 
The CHA2DS2-VASc score may identify patients at higher risk of atrial fibrillation (AF) 
following ischemic stroke (IS) among patients without known AF. We compared gender-
related differences in items from CHA2DS2-VASc score and their relationship with AF 
occurrence after IS. This French cohort study was based on the database covering hospital 
care from 2009 to 2012 for the entire population. Of 336,291 patients with IS, 240,459 
(71.5%) had no AF at baseline. Women were older, more frequently had hypertension, heart 
failure, and had a higher CHA2DS2-VASc score than men (4.63 vs 4.39, p<0.0001, after 
excluding the female gender component). The annual incidence of AF after IS was higher in 
women than in men (9.8 vs 8.2%/year, p<0.0001). CHA2DS2-VASc score items were 
independent predictors of incident AF, except diabetes and vascular disease. Results were 
similar in men and women when one analyzed separately these predictors except for vascular 
disease (associated with a lower risk of AF in women but not in men). Predictive value of the 
CHA2DS2-VASc score for identifying patients at higher risk of incident AF was somewhat 
higher in men (C statistic 0.720, 95%CI 0.717-0.722) than in women (0.702, 95%CI 0.699-
0.704). Coronary artery disease, valvular disease and history of pacemaker/defibrillator 
implantation were also independent predictors of incident AF.  In conclusion, there were 
significant differences in comorbidities, possible mechanisms, incidence and predictors of AF 
between men and women after IS. However, a strategy using CHA2DS2-VASc score for 
identifying a higher risk of incident AF following IS was useful in both genders. 
 
Key words: atrial fibrillation, ischemic stroke, risk prediction  
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Introduction 
One in five of all ischemic strokes (IS) can be attributed to atrial Fibrillation (AF) 
1
. 
The risk of recurrence is 22% in cases of cardio embolic stroke 
2  
and oral anticoagulation 
would be needed for patients with AF. Documentation of AF by electrocardiogram is 
generally required to initiate oral anticoagulation for secondary prevention after IS, but in the 
absence of documented AF, antiplatelet agents are usually recommended 
3
. A simple way to 
‘flag up’ patients with a high risk of developing incident AF after IS for more intense 
monitoring strategies or follow-up would help management. The CHA2DS2-VASc score has 
been widely used to estimate the risk of stroke in patients with AF 
4
 and for adverse outcomes 
even in patients without known AF 5,6. Its usefulness for prediction of new AF in patients after 
IS has also been observed in a French Nationwide Cohort Study
 7
.  AF has been associated 
with a stronger relative risk of IS in women than in men
 8,9
. Importantly, mechanisms and 
comorbidities associated with AF incidence may differ between men and women 
10
.  We 
aimed to compare gender-related differences in items from CHA2DS2-VASc score and their 
relationship with differences in AF occurrence between men and women after IS.  
 
METHODS 
  This French longitudinal cohort study was based on the national hospitalization 
database covering hospital care from for the entire population. The main outcome measure 
was rate of incident AF. Data for all patients admitted with IS in France from January 2008 to 
December 2012 were collected from the national administrative database, the PMSI 
(Programme de Médicalisation des Systèmes d’Information), inspired by the US Medicare 
system. Since 2004, each hospital’s budget has been linked to the medical activity described 
in this specific program, which compiles discharge abstracts related to all admissions for 
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inpatients in the 1,546 French healthcare facilities. The reliability of PMSI data has already 
been assessed 11 and has previously been used to study patients with stroke and AF 
7,12,13
.  
This study was approved by the institutional review board of the Pole Coeur Thorax 
Vaisseaux from the Trousseau University Hospital, on December 1, 2015 and registered as a 
clinical audit. Ethical review was therefore not required. Patient consent was not sought. The 
study was conducted retrospectively, patients were not involved in its conduct, and there was 
no impact on their care. Procedures for data collection and management were approved by the 
Conseil National de l'Informatique et des Libertés, the independent National ethical 
committee protecting human rights in France which ensures that all information is kept 
confidential and anonymous (authorization number 1749007). 
The study included adults (≥18 years) with a diagnosis of acute IS (I63 and its 
subsections using ICD10 codes) coded in the principal diagnosis (i.e. the health problem that 
justified admission to hospital), the related diagnosis (i.e. potential chronic disease or health 
state during hospital stay) or the significantly associated diagnosis (i.e. comorbidity or 
associated complication) who were hospitalized from January 1, 2008 to December 31, 2012. 
We made an analysis restricted to the patients seen after 2009, meaning that all patients had at 
least 1 year where previous events were recorded to establish history of previous AF and 
comorbidities. Patients with no diagnosis of AF were considered as having sinus rhythm. Of 
note, asymptomatic cerebrovascular diseases and sequelae of stroke have different codes (I65-
I66 and I69 with subdivisions) to be distinguished from acute strokes in the patients of our 
analysis. Patient information (demographics, comorbid conditions, medical history, and 
events during follow-up or during hospitalization) was described using data collected in the 
hospital records. For each hospital stay, all diagnoses were obtained together at discharge. We 
calculated the CHA2DS2-VASc score as previously described 
4
.  
Qualitative variables are described using counts and percentages, and continuous 
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quantitative variables as means ± standard deviation or median (IQR, interquartile range). 
Comparisons were made using parametric or non-parametric tests as appropriate: The 
Wilcoxon W and Kruskal – Wallis tests were used for comparing values between two 
independent groups and the X
2
 test for comparing categorical data. The population of 
individuals seen with IS without prior AF was analysed by calculating incidence rates of new 
onset AF and by multivariable Cox regression models. A proportional hazard model was used 
to identify independent characteristics associated with the occurrence of AF during follow-up. 
Receiver operating characteristic (ROC) curves were constructed and the Harrell’s c statistics 
were calculated as a measure of model performance and compared using the DeLong test. In 
all analyses, a p value <0.05 was considered statistically significant. All analyses were 
performed using JMP 
®
 9.0.1 (SAS Institute, Cary, NC, USA) and Statview 5.0 (Abacus, 
Berkeley CA, USA). 
 
RESULTS 
Of 336,291patients with IS from 2009 to 2012 with a known rhythm status before and 
after IS, we identified 240,459 (71.5%) as not having AF at baseline and 95,832 (28.5%) with 
previously known AF (based on their clinical history or during their hospital stay with 
diagnosis of stroke) (figure 1). Baseline characteristics of patients without AF at baseline 
indicated that more than half were aged ≥75 years with significant differences in associated 
comorbidities between men and women (Table 1). Women were significantly older, more 
frequently had hypertension, congestive heart failure, and had a higher CHA2DS2-VASc 
score. CHA2DS2-VASc score after excluding the female gender component (1 point) 
remained higher in women than men (4.63 vs 4.39, p<0.0001). Women also more frequently 
had valvular disease and anaemia. By contrast, they less frequently had dyslipidaemia, 
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tobacco smoking, coronary artery or vascular disease, pacemaker or defibrillator implantation, 
renal failure, lung disease or history of cancer. 
Of these patients, a total of 14,095 (5.9%) without AF at baseline, were diagnosed as 
having incident AF during a subsequent hospitalization over a mean follow-up of 7.9±11.5 
months (Table 2). The total yearly incidence rate for AF for participants with IS was 8.9 per 
100 person-years (95% confidence interval [CI] 8.8-9.0-7.9). Patients with AF during follow-
up were significantly older, including a higher proportion of women, and more prevalent 
items of the CHA2DS2-VASc score than patient without AF during follow-up. 
Predictors of incident AF are shown in Table 3 for the whole population, and in Table 
4 for men and for women. In the whole population, most powerful predictors of incident AF 
(hazard ratio [HR]  ≥1.20) were older age, hypertension, heart failure (among items of the 
CHA2DS2-VASc score), coronary artery disease, valvular disease and history of 
pacemaker/defibrillator implantation. The association between vascular disease and AF 
occurrence was weaker and borderline to significance for female gender after adjusting for 
other items. Diabetes mellitus was associated with a higher incidence of AF in univariate 
analysis but was independently associated with a lower rate of incident AF on multivariable 
analysis. Results were broadly similar when one analysed separately men and women, except 
for obesity, abnormal renal function and anaemia (predictor of incident AF in men whilst not 
significant predictors of AF in women).  
The CHA2DS2-VASc score predicted subsequent hospital discharge with a new 
diagnosis of AF in those patients with IS without pre-existing AF at baseline. Increasing 
CHA2DS2-VASc score was associated with higher risk of new onset (or previously 
undiagnosed) incident AF during follow-up (HR 1.43 CI 1.41-1.45, HR 1.48 CI 1.45-1.50 in 
men and HR 1.46 CI 1.44-1.49 in women) (Figure 2). The annual incidence of AF increased 
in a stepwise fashion and reached 18.8% in patients with highest CHA2DS2-VASc score =9 
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(only women) and 20.1% for men with CHA2DS2-VASc score =8 (Figure 3). In patients with 
no other CHA2DS2-VASc score item, women with IS (thus, CHA2DS2-VASc score =3) had a 
lower incidence of AF during follow-up than men with IS (CHA2DS2-VASc score =2) (1.3% 
vs 2.0%) but the total incidence in women was higher when considering the whole population 
of the study (9.8% for women vs 8.2% for men).  
ROC curve analysis for prediction of AF by the CHA2DS2-VASc score showed an 
area under the curve at 0.7025 (95%CI 0.7007-0.7043), with a sensibility of 68.3%, a 
specificity of 62%, a positive predictive value of 10.1% and a negative predictive value of 
96.9% for a cut off score ≥6. Predictive value of the CHA2DS2-VASc score for identifying 
patients at higher risk of incident AF was somewhat higher in men (C statistics 0.720, 95%CI 
0.717-0.722) than in women (0.702, 95%CI 0.699-0.704; De Long test, p<0.0001).  
 
DISCUSSION 
Our results confirm that IS was associated with substantially increased risk of AF 
among individuals with higher CHA2DS2-VASc score, as previously reported 
16
. However, 
we extend prior observations by showing significant differences in comorbidities and 
incidence of AF in men and women after IS. Furthermore, CHA2DS2-VASc had a slightly 
better ability to predict incident AF diagnosed in men than in women after IS. Thus, this score 
would be a simple way to ‘flag up’ high risk patients for more intense monitoring strategies or 
follow-up (even in primary care) would help the holistic management of such patients. 
Women and men may have different sequelae to various risk factors for cardiovascular 
disease 
9,14
. Previous analyses have shown that smoking and diabetes are associated with 
greater proportional risks of coronary heart disease in women than in men 
15,16
. It is currently 
unclear, however, whether such sex differences exist for incident AF, whilst conversely AF is 
a stronger risk factor for cardiovascular disease and death in women compared with men 
9,17
. 
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The CHA2DS2-VASc score is a validated tool to estimate the risk of stroke in patients with 
documented AF. The pre-stroke CHA2DS2-VASc score has also been associated with 
neurological outcomes following IS in patients with AF 
18,19
. It has also been linked to long- 
term mortality, stroke recurrence and cardiovascular events in IS patients without AF 
20
. The 
CHA2DS2-VASc score has also been useful in predicting the risk of incident AF in a large 
population 
21
 and in patients after IS 
7
. Whether this simple score works similarly in men and 
women has not been previously established.  
We found marked differences in baseline characteristics of men and women 
experiencing IS, whereby women were older and had more hypertension, heart failure and 
accordingly a higher CHA2DS2-VASc score. By contrast, they less frequently had coronary or 
vascular disease, lung disease or renal failure, which may be due to their lower prevalence of 
dyslipidaemia and tobacco smoking at baseline. The incidence of new incident AF was high, 
and this rises the possibility that IS was cardioembolic in a vast part of this population, 
although we were not able to identify the subtypes of IS. The annual incidence of AF after IS 
was greater in women than in men. The older age, more frequent comorbidities and higher 
CHA2DS2-VASc score at baseline in women may explain these results. An easier and earlier 
diagnosis of AF might be possible in women because asymptomatic AF is less common in 
females
22
, which may be related to their older age and more frequent comorbidities.  
There are few tools integrating multiple risk factors to establish an individual’s 
absolute risk of incident AF post-stroke while risk factors such as ageing, diabetes mellitus, 
hypertension, obesity, and cardiovascular disease, including alterations in cardiac structure 
and function consistently predispose individuals to AF 
23–25
. Many components of the 
CHA2DS2-VASc scores are associated with higher prevalence of AF. Consistently reported 
risk indicators of incident AF in the general population or after IS were sex, older age, body 
mass index, hypertension, heart failure, myocardial infarction and valvular heart disease 
7,23,25
.  
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We found that diabetes mellitus was independently associated with a lower risk of AF 
after IS. Previous epidemiological studies have reported on the association between diabetes 
mellitus and subsequent risk of AF, with inconsistent results 
26
. Diabetes seems less strongly 
associated with AF than with other cardiovascular diseases and the causality link between 
diabetes and AF has been debated because of the frequent association with hypertension and 
obesity. In several cohort analyses, diabetes was less frequent in patients with cardioembolic 
stroke than in patients with other causes of IS 
2,27,28
. Patients with diabetes could also be 
exposed to more silent AF and our study did not evaluate this issue. 
Similarly, vascular disease (as defined in the CHA2DS2-VASc score) was associated 
with a lower AF incidence in women. We may hypothesize that vascular disease is more 
likely to be associated with large artery or small vessel pathology in women with IS (and less 
likely to be associated with IS of thromboembolic origin),  which may explain the lower 
association with incident AF occurrence in spite of females being older than males at baseline. 
This might also explain why the CHA2DS2-VASc score had a lower predictive ability to 
identify the risk of incident AF in women compared to men in our analysis. However, 
coronary artery disease per se was associated with a higher incidence of AF in both genders.  
In spite of these differences, the CHA2DS2-VASc score was able to predict subsequent 
AF in those patients with IS in both genders similarly, although the diagnostic value of the 
CHA2DS2-VASc score was slightly higher in men. Higher scores identified patients more 
likely to develop incident AF, and our findings help targeting patients at highest risk of AF in 
both groups of male and female patients. Some other characteristics not included in the 
CHA2DS2-VASc score may also help to identify a higher risk of subsequent AF, particularly a 
history of coronary artery disease or valvular disease. In males with IS, obesity (which may be 
related to a critical size of the atrium) and anaemia (for unclear reasons) may also marginally 
identify a higher risk of AF. Patients with a CHA2DS2-VASc score of 6 (as per and above 
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who have sustained an ischemic stroke might have the likelihood of AF high enough to 
warrant oral anticoagulation before the arrhythmia is formally documented or, more in 
common with the current opinion, encourage enhanced screening for AF. However, the 
intensity of such a screening procedure and the duration of clinical/monitoring follow-up have 
not yet been established and are beyond the scope of this analysis. 
A limitation of this study is inherent to its retrospective observational nature. Even 
though the reliability of PMSI data has been verified previously 
11
 and used for 
epidemiological purposes in AF 
7,13
, the analysis presents inherent potential information bias. 
The study methodology possibly underestimated the true incidence of AF in this population 
and may overestimate the importance of the components of the CHA2DS2-VASc score and 
comorbidities, which might predispose to hospitalization. Besides, some echocardiographic 
parameters may help to identify risk of AF 
27
, and these parameters were lacking in the 
present study. However, the goal of the present study was to use a simple clinical risk score 
for predicting the risk of new-onset AF in patients without performing further examinations. 
Considering its often paroxysmal and asymptomatic nature, AF may not be detected very 
early with the use of traditional monitoring techniques 
29,30
. The analysis also presents 
inherent potential for information bias, given that no information was available for 
medications, drug misuse, and international normalized ratios.  
In conclusion, among IS patients without known AF, the CHA2DS2-VASc score is 
simple risk tool for identifying patients at higher risk of developing incident AF following IS. 
Whilst there were significant differences in comorbidities, possible mechanisms and incidence 
of AF between men and women after IS, a strategy using CHA2DS2-VASc score for 
identifying a higher risk of incident AF was similarly useful in both genders. 
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Figure legends 
 
 
Figure 1. Flow chart of the study patients.  
a 
Sinus rhythm or AF. AF indicates atrial fibrillation; CHA2DS2-VASc, congestive heart 
failure, hypertension, age ≥75 years (doubled), diabetes mellitus, stroke/transient ischemic 
attack (doubled), vascular disease, age 65-74 years, and sex category (female); and IS, 
ischemic stroke. 
 
 
Figure 2. The Kaplan–Meier curves indicate that patients with ischemic stroke and higher 
CHA2DS2-VASc scores had higher rates of new-onset atrial fibrillation (AF) during the 
follow-up period in men (Upper panel) and in women (Lower panel). CHA2DS2-VASc 
indicates congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, 
stroke/transient ischemic attack (doubled), vascular disease, age 65–74 years, and sex 
category (female); and CI, confidence interval.  
 
Figure 3. Hazard ratio of new onset atrial fibrillation in patients with ischemic stroke with 
different CHA2DS2-VASc scores (in comparison to the patients with score of two) in men 
and (in comparison to the patients with score of two) in women. 
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Table 1 Baseline characteristics of the patients with ischemic stroke and no known atrial 
fibrillation at baseline. 
 
Variable  Study population, 
(n=240,459) 
Men 
(n=126,111) 
Women 
(n=114,348) 
p value 
Age (years)  
Age ≥75 years old 
Underlying diseases 
Hypertension  
Diabetes mellitus  
Congestive heart failure  
Vascular disease  
CHA2DS2-VASc score 
71.2±15.5 
120,537(50.2%) 
 
152,790(63.5%) 
55,060(22.9%) 
39,423(16.4%) 
77,543(32.3%) 
4.98±1.63 
68.3±14.5 
49,493(39.3%) 
 
78,917(62.6%) 
31,558(25.0%) 
20,129(16.0%) 
48,252(38.3%) 
4.38±1.53 
74.2±16 
71,044(62.2%) 
 
73,873(64.6%) 
23,502(20.6%) 
19,294(16.9%) 
29,291(25.6%) 
5.63±1.47 
<0.0001 
<0.0001 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.0001 
Coronary artery disease 44,621(18.6%) 27,803(22.1%) 16,818(14.7%) <0.0001 
Obesity * 24,972(10.4%) 13,013(10.3%) 11.959(10.5%) 0.26 
Abnormal renal function 44,011(18.3%) 23,625(18.7%) 20,386(17.8%) <0.0001 
Liver disease 7,298(3.0%) 4,644(3.7%) 2,654(2.3%) <0.0001 
Anemia * 35,145(14.6%) 16,217(12.9%) 18,928(16.6%) <0.0001 
Lung disease 38,981(16.2%) 23,094(18.3%) 15,887(13.9%) <0.0001 
Cancer within preceding 5 years 40,456(16.8%) 24,364(19.3%) 16,092(14.1%) <0.0001 
Inflammatory diseases 15,656(6.5%) 8,127(6.4%) 7,529(6.6%) 0.17 
Alcohol-related diagnoses 18,634(7.8%) 14,895(11.8%) 3,739(3.3%) <0.0001 
Thyroid disease 74,287(30.9%) 39,228(31.1%) 35,059(30.7%) 0.02 
Dyslipidemia * 75,221(31.3%) 43,535(34.5%) 31,686(27.7%) <0.0001 
Pacemaker-cardioverter 
defibrillator implantation  
8,844(3.7%) 5,377(4.3%) 3,467(3.0%) <0.0001 
Valvular heart disease 17,901(7.4%) 9,203(7.3%) 8,698(7.6%) 0.004 
Tobacco smoker 30,255(12.6%) 22,794(18.1%) 7,461(6.5%) <0.0001 
 
 * Obesity defined as International Classification of Disease 10 (ICD-10) codes E65–E66; 
Anemia defined as ICD codes D50–D64; Dyslipidemia defined as ICD code E78 
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Table 2 Baseline characteristics of the patients with ischemic stroke and no known atrial 
fibrillation at baseline according to atrial fibrillation occurrence during follow-up. 
 
Variables  AF during follow-up 
(n=14,095) 
No AF during follow-
up 
(n=226,364) 
p value 
Age (years) 
Age ≥75-year old  
Women  
Hypertension  
Diabetes mellitus  
Congestive heart failure  
Vascular disease  
CHA2DS2-VASc score 
77.6±10.6 
9,755(69.2%) 
7,082(50.3%) 
11,745(83.3%) 
4,083(29%) 
6,261(44.4%) 
6,907(49%) 
6.08±1.44 
70.8±15.7 
110,782(49%) 
107,266(47.4%) 
141,045(62.3%) 
50,977(22.5%) 
33,162(14.7%) 
 70,636(31.2%) 
4.91±1.61 
<0.0001 
<0.0001 
<0.0001 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Coronary artery disease 4,969(35.3%) 39,652(17.5%) <0.0001 
Obesity 2,071(14.7%) 22,901(10.1%) <0.0001 
Abnormal renal function 5,393(38.3%) 38,618(17.1%) <0.0001 
Liver disease 593(4.2%) 6,705(3.0%) <0.0001 
Anemia 3,980(28.2%) 31,165(13.8%) <0.0001 
Lung disease 3,661(26.0%) 35,320(15.6%) <0.0001 
Cancer within preceding 5 years 3,056(21.7%) 37,400(16.5%) <0.0001 
Inflammatory diseases 1,470(10.4%) 14,186(6.3%) <0.0001 
Alcohol-related diagnoses 954(6.8%) 17,680(7.8%) <0.0001 
Thyroid disease 6,040(42.9%) 68,247(30.2%) <0.0001 
Dyslipidemia 5,793(41.1%) 69,428(30.7%) <0.0001 
Pacemaker-cardioverter defibrillator 
implantation 
1,643(11.7%) 7,201(3.2%) <0.0001 
Valvular disease 2.780(19.7%) 15.121(6.7%) <0.0001 
Tobacco smoking 1,415(10.0%) 28,840(12.7%) <0.0001 
 
 
Page 19 of 24
20 
 
Table 3. Cox regression analysis for prediction of atrial fibrillation after ischemic stroke for 
items constituting the CHA2DS2-VASc score and other baseline characteristics in the overall 
population. 
 Univariate analysis 
(overall population) 
Multivariable analysis (overall 
population) 
Covariate HR(95%CI) P-value HR(95%CI) P-value 
Age 65–74 years 0.85 (0.82-0.89) <0.0001 1.99 (1.87-2.12) <0.0001 
Age ≥75 years 2.54 (2.45-2.63) <0.0001 2.86 (2.70-3.02) <0.0001 
Female gender 1.21 (1.17-1.25) <0.0001 1.05 (1.01-1.09) 0.0095 
Hypertension 1.90 (1.81-1.98) <0.0001 1.24 (1.18-1.30) <0.0001 
Diabetes 1.07 (1.04-1.11) <0.0001 0.89 (0.85-0.92) <0.0001 
Heart failure 2.99 (2.89-3.09) <0.0001 2.05 (1.97-2.13) <0.0001 
Vascular disease 1.42 (1.37-1.46) <0.0001 0.90 (0.85-0.94) <0.0001 
Systemic embolism 1.37 (1.28-1.47) <0.0001 1.20 (1.11-1.29) <0.0001 
Coronary artery disease 1.70 (1.64-1.76) <0.0001 1.22 (1.15-1.28) <0.0001 
Obesity 1.07 (1.02-1.12) 0.0064 1.05 (1.00-1.11) 0.0460 
Abnormal renal function 2.02 (1.96-2.09) <0.0001 1.12 (1.07-1.17) <0.0001 
Liver disease 1.01 (0.93-1.10) 0.7536 1.05 (0.97-1.15) 0.2440 
Anaemia 1.53 (1.47-1.58) <0.0001 1.10 (1.06-1.15) <0.0001 
Lung disease 1.42 (1.36-1.47) <0.0001 1.14 (1.09-1.18) <0.0001 
Cancer within preceding 5 years 0.95 (0.91-0.99) 0.007 0.92 (0.89-0.96) 0.0002 
Inflammatory diseases 1.13 (1.07-1.20) <0.0001 0.95 (0.90-0.99) 0.0485 
Alcohol-related diagnoses 0.66 (0.62-0.71) <0.0001 0.96 (0.89-1.03) 0.2126 
Thyroid disease 1.02 (0.99-1.06) 0.2086 0.97 (0.93-1.00) 0.0670 
Dyslipidemia 1.06 (1.03-1.10) 0.0005 0.97 (0.93-1.00) 0.0773 
Pacemaker-cardioverter 
defibrillator implantation 2.67 (2.53-2.81) <0.0001 
1.56 (1.48-1.64) <0.0001 
Valvular disease 2.41 (2.31-2.51) <0.0001 1.44 (1.37-1.51) <0.0001 
Tobacco smoking 0.63 (0.59-0.66) <0.0001 0.92 (0.86-0.98) 0.0055 
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Table 4. Cox regression analysis for prediction of atrial fibrillation after ischemic stroke for 
items constituting the CHA2DS2-VASc score and other baseline characteristics in men and in 
women. 
 Multivariable analysis  
(in men) 
Multivariable analysis  
(in women) 
Covariate HR(95%CI) P-value HR(95%CI) P-value 
Age 65–74 years 1.79 (1.66-1.94) <0.0001 2.40 (2.15-2.68) <0.0001 
Age ≥75 years 2.58 (2.40-2.77) <0.0001 3.32 (3.02-3.67) <0.0001 
Female gender - - - - 
Hypertension 1.17 (1.10-1.25) <0.0001 1.30 (1.21-1.39) <0.0001 
Diabetes 0.93 (0.88-0.98) 0.0039 0.85 (0.80-0.90) <0.0001 
Heart failure 1.99 (1.88-2.10) <0.0001 2.11 (2.00-2.22) <0.0001 
Vascular disease 0.94 (0.87-1.01) 0.0804 0.86 (0.80-0.93) <0.0001 
Systemic embolism 1.09 (0.98-1.19) 0.1021 1.36 (1.21-1.52) <0.0001 
Coronary artery disease 1.21 (1.13-1.30) <0.0001 1.22 (1.12-1.32) <0.0001 
Obesity 1.10 (1.03-1.18) 0.0073 1.03 (0.96-1.10) 0.4737 
Abnormal renal function 1.18 (1.11-1.25) <0.0001 1.06 (0.99-1.13) 0.0722 
Liver disease 1.06 (0.95-1.19) 0.2855 1.03 (0.90-1.18) 0.6568 
Anaemia 1.21 (1.15-1.28) <0.0001 1.01 (0.96-1.07) 0.7463 
Lung disease 1.17 (1.11-1.24) <0.0001 1.10 (1.04-1.17) 0.0015 
Cancer within preceding 5 
years 
0.94 (0.89-0.99) 0.0165 0.91 (0.86-0.97) 0.0044 
Inflammatory diseases 0.97 (0.89-1.04) 0.3915 0.93 (0.86-1.00) 0.0641 
Alcohol-related diagnoses 0.96 (0.88-1.04) 0.2841 0.88 (0.75-1.02) 0.0968 
Thyroid disease 0.96 (0.91-1.10) 0.0758 0.98 (0.94-1.03) 0.4740 
Dyslipidemia 0.95 (0.90-0.99) 0.0483 0.98 (0.93-1.03) 0.4215 
Pacemaker-cardioverter 
defibrillator implantation 
1.58 (1.47-1.69) <0.0001 1.54 (1.41-1.67) <0.0001 
Valvular disease 1.35 (1.26-1.45) <0.0001 1.54 (1.43-1.65) <0.0001 
Tobacco smoking 0.93 (0.87-0.99) 0.0446 0.86 (0.75-0.97) 0.0164 
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